ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against Stress-Induced Affective…

Source

Previous articlePharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
Next articleEhave Provides Progress Update on its HPPD Study with University of Melbourne